Federal Project Grant Award Summary

The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of North Carolina at Chapel Hill a five-year Project Grant of $166,924.00 (Award Date: July 1, 2026; Ultimate Completion Date: June 30, 2031) under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on cell surface localization of Factor VIII (FVIII) mimetic therapy. Hemophilia A, an inherited bleeding disorder caused by FVIII deficiency, requires prophylactic FVIII concentrate treatment as the current standard of care for severe cases to prevent life-threatening hemorrhage. This research project is designed to advance therapeutic approaches to address this coagulation deficiency through investigational FVIII mimetic technologies.

The award funds basic and translational research activities conducted at UNC-Chapel Hill's Chapel Hill, North Carolina facility, where the University's Office of Sponsored Research serves as the prime recipient. The project aligns with the NHLBI's mission to foster hypothesis-driven research across cardiovascular and blood disease pathology, with the ultimate objective of developing improved treatment modalities for hemophilia patients. Deliverables will include scientific findings, experimental results, and research documentation generated through the funded investigation period.